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Anticonvulsants in Bipolar Disorder 
Abstract 
The aim of this article is to give a condensed overview of the putative mechanisms of action 
and clinical effectiveness of anticonvulsants in Bipolar disorder (BD).  This article is not a 
full review of the evidence, but an educational paper highlighting findings which the author 
feels are of importance to understand mechanisms of action and clinical effectiveness of 
anticonvulsants in Bipolar disorder. The main findings are some striking similarities between 
the modes of action of lithium and some anticonvulsants, involving mainly intracellular 
cascades of signaling and related structural changes.  Clinically, there is good evidence for 
beneficial effects of most ACs in BD and especially for carbamazepine, valproate and 
lamotrigine, but also phenytoin, oxcarbazepine, levetiracetam, gabapentin, topiramate and 
zonisamide may be helpful in selected patients.  
Introduction 
Anticonvulsant drugs are widely used in psychiatry including for alcohol and benzodiazepine 
withdrawal symptoms, panic and anxiety disorders, dementia, schizophrenia, and, to some 
extent, personality disorders. They are also used in pain syndromes. However, their main 
usage outside epilepsy, is bipolar disorder. Carbamazepine, valproate, and lamotrigine are 
recognized mood stabilizers, but several other antiepileptic drugs have also been tried out 
with diverging or inconclusive results. Having a better understanding of the mechanisms of 
action and identifying similarities between anticonvulsants effective in bipolar disorder may 
enhance our knowledge of the underlying pathophysiology of the disorder and help to refine 
its treatment. 
Mood changes in particular are a common symptom in epileptic patients, and some 
anticonvulsants (ACs) seem to contribute to it. Whereas negative effects on mood and anxiety 
states have been described quite frequently with the first generation of ACs, especially 
bromine and later barbiturates, it was in the 1960s and early 70’s when observations were first 
published describing mood stabilising effects of valpromide (Lambert & Venaud, 1966), 
phenytoin (Turner, 1967) and carbamazepine (CBZ)(Okuma, Kishimoto, Inoue, Matsumoto, 
& Ogura, 1973). These mood stabilizing effects included aspects of both manic/ aggressive 
behaviour as well as depressive symptoms, but those studies did not look at long term 
maintenance of euthymia, which is nowadays included in the definition of a “mood 
stabiliser”. Nowadays, a number of ACs has proven or, at least, assumed efficacy in treating 
mood-disordered patients.  This article aims to give a condensed overview on their proposed 
mechanism of action and the clinical effectiveness of different ACs in bipolar disorder (BD). 
Although safety and tolerability are aspects of utmost importance, they will not be dealt with 
in this article for the sake of space. However,  knowledge of thel tolerability and safety issues 
of ACs is vital before applying them in routine practice. Recent reviews (e.g., (Singh, Muzina, 
& Calabrese, 2005) are a comprehensive source of information for further reading. 
 Mechanism of action of ACs with respect to BD 
 
Until the discovery of antipsychotics and lithium for the treatment of BD, electroconvulsive 
therapy (ECT) was the only available treatment for depression (Geddes, 2003) but also for 
mania (Mukherjee, Sackeim, & Schnur, 1994). Although the decisive cellular mechanisms 
remain speculative, it appears that with every application of ECT the seizure threshold 
increases. Thus, ECT has, paradoxically, an anticonvulsive effect. Interestingly, manic 
patients also show an increase of seizure threshold with fading manic symptomatology 
(Mukherjee 1989). Assuming that mania is associated with increased neuronal excitability, 
these observations supply a clinical rationale for using ACs in the acute treatment of mania.  
But how do ACs (and probably ECT) alter brain function? When considering the cellular 
mode of action of AC, we have to distinguish between three different levels: synaptic 
transmission, intracellular signalling and finally, gene activation and structural changes that 
may increase vulnerability to relapse. Following this hierarchy, we will first briefly touch on 
the impact of AC’s on the metabolism and the synaptic action of biogenic amines. 
 
Modulation of the action of biogenic amines by AC’s 
GABA 
 
The most ubiquitous and powerful inhibitory neurotransmitter in the brain is γ-amino-butyric 
acid (GABA). In a genome-wide association analysis of BD, one of the most strongly 
associated polymorphisms was found within the gene encoding the GABA (A) receptor beta1 
subunit, GABRB1. In addition, also polymorphisms in the GABA A receptor subunits 
GABRA4, GABRB3, GABRA5 and GABRR1 seem to be associated with BD (Craddock et 
al., 2008). Although a recent magnetic resonance spectroscopy (MRS) study trying to show 
directly altered GABA metabolism in Bipolar patients failed (Kaufman et al., 2009), 
alterations of GABA transmission are still a strong candidate for an underlying cause in BD. 
Both CBZ and VPA exhibit agonistic effects on the GABAergic system. CBZ is a positive 
modulator of the GABA A receptor increasing the GABA A receptor mediated chloride 
current (Granger et al., 1995). VPA increases GABA release in different areas of the brain 
(Emrich & Wolf, 1992). However, we have to note that two potentially specific GABAergic 
ACs, gabapentin and tiagabine, appear not as efficacious in BD. Another highly specific 
GABAergic compound, vigabatrine, has even been associated with the induction of affective 
disorders and psychosis in epileptic patients (Sander, Hart, Trimble, & Shorvon, 1991) or to 
cause mania (Naumann, Supprian, Kornhuber, Lange, & Reiners, 1994). 
Excitatory amino acids 
 
Glutamate is the main excitatory neurotransmitter in the brain, and exerts a multitude of 
actions via NMDA, AMPA/ Kainate and metabotrophic receptors (m-GLU receptors). CBZ 
has been described to enhance the activity of the glutamate transporter type 3 (Lee, Huang, 
Washington, Briggs, & Zuo, 2005). Inhibition of NMDA-receptor mediated currents has been 
reported for CBZ (Lampe and Bigalke 1990) in animal studies. Chronic administration of 
both CBZ and VPA reduces brain NMDA signalling via arachidonic acid (Basselin, Chang, 
Chen, Bell, & Rapoport, 2008; Basselin, Villacreses, Chen, Bell, & Rapoport, 2007). LTG 
inhibits the release of glutamate and aspartate. However, this appears  to be an effect mediated 
by the blockade of sodium channels rather than a direct effect on synthesis and release of 
excitatory amino acids (Choi & Morrell, 2003). Sodium channel blockade may in fact have a 
protective effect against NMDA- hypofunction mediated cytotoxicity, and several ACs with  
properties (CBZ, VPA, LTG, phenytoin) share this mechanism (Farber, Jiang, Heinkel, & 
Nemmers, 2002). It remains unclear however what the absolute contribution of action directed 
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against excitatory amino acids is to antiepileptic potencies of these drugs and even more 
speculatively, to efficacy in BD.  
 
Dopamine 
 
Catecholamines have been implicated in the pathophysiology of affective disorders for more 
than three decades (Buki & Goodnick, 1998), either alone or in the context of a 
noradrenergic- cholinergic dysbalance theory. Genetic findings suggest a role of the dopamine 
D4 receptor gene (Manki et al 1996), the dopamine transporter gene (Waldman, Robinson, & 
Feigon, 1997) and the gene encoding for DARPP 32, a dopamine and cyclo-AMP regulated 
phosphoprotein (Ogden et al., 2004) although it remains unclear which mutations are of 
relevance for developing bipolar disorder. The dopamine hypothesis of mania was proposed 
some time ago (Diehl & Gershon, 1992) and mainly dopaminergic acting antipsychotics such 
as haloperidol are still first line choices when treating acute mania.  
Whereas ACs seem to do little on norepinephrine turn-over (with the possible exception of 
LTG (Kaster, Raupp, Binfare, Andreatini, & Rodrigues, 2007)), VPA exerts  modulatory 
effects on dopaminergic transmission. 
VPA increases the CNS dopamine turnover in animal models (Löscher and Hoenack 1996), 
but  reduces presynaptic dopamine reuptake in man (Yatham et al., 2002b). Similar effects on 
dopamine are not seen for CBZ (Sokomba et al 1988). A direct effect of VPA on D2 receptor 
blockade in mania, similar to that found for antipsychotics, could not be verified (Yatham et 
al., 2002a).  
Serotonin 
 
The receptor pharmacology of serotonin is even more complex than that of dopamine and 
provides a range of ways in which serotonin could play an important role in BD. Serotonergic 
hypofunction has been implicated as an underlying disturbance in mania (Maes et al 1997). 
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The AA genotype of the tryptophan hydroxylase, the rate limiting enzyme of serotonin 
synthesis, seems to be asssociated with an enhanced risk of developing BD (Chen, Glatt, & 
Tsuang, 2008). Lithium and most modern atypical antipsychotics are? used in BD work, at 
least in part, by modulating serotonergic transmission. An increase of extracellular serotonin 
has been observed with VPA (Whitton et al 1985) and CBZ treatment in animal models 
(Dailey et al 1997), and in vitro for LTG (Southam et al 1997; von Wegerer et al 1997a). 
However, it is clearly difficult to estimate the contribution of serotonin modulation to the 
beneficial effects of these drugs as ACs are anything but specific for the serotonergic system. 
 
Effects of ACs on intracellular messaging systems 
 
Activation of receptors of biogenic amines initializes a cascade of intracellular signalling that 
finally leads to the expression of early genes. ACs may, however, interfere with this cascade 
on different levels of the signalling pathways, either from the inside of the cell or by blocking 
transmembraneous ion fluxes. Modulation of sodium currents have already been mentioned as 
a mechanism that may protect against NMDA hypofunction mediated neurotoxicity (Farber et 
al., 2002). In addition, there is evidence that a deranged intracellular calcium homeostasis 
may be a feature in BD (Dubovsky & Franks, 1983). Excessive intracellular calcium may 
cause neuronal loss by activating calcium dependent proteases and phospholipase A 
(Bachmann, Schloesser, Gould, & Manji, 2005).  
Potentially beneficial effects of ACs through interference with intracellular calcium signalling 
have been reported in various pathways. A decreased Na, K ATPase activity has been 
described as a state marker in acutely ill bipolar patients as it is not seen in healthy relatives 
(Antia, Smith, Wood, & Aronson, 1995). CBZ  stimulates  Na, K ATPase causing a reduction 
of intracellular calcium- an effect also seen with lithium (Wood, Elphick, & Grahame-Smith, 
1989). Similar to lithium, CBZ and VPA also reduce the activity of protein kinase A and C by 
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reducing cAMP dependent protein phosphorylation (Rao, Bazinet, Rapoport, & Lee, 2007a; 
Du et al., 2008). A decrease of cAMP dependent protein phosphorylation, in turn, also leads 
to reduced gene expression of proteins responsible for neurotransmission (Jensen & Mork, 
1997). Protein kinase C (PKC) inhibition might therefore be a crucial antimanic mechanism 
of action, and the PKC inhibitor tamoxifen has also proven antimanic efficacy in clinical trials 
(Yildiz, Guleryuz, Ankerst, Ongur, & Renshaw, 2008) 
However, ACs may also effect voltage dependent calcium channels directly. This has been 
demonstrated in vitro for CBZ (Walden et al 1992), VPA (Macdonald and Kelly 1995) and 
LTG (Wegerer, Hesslinger, Berger, & Walden, 1997). Another action on ion channels 
induced by CBZ, VPA and LTG, and potentially important for the suppression of seizures, is 
the facilitation of an early transient potassium outward current (Olpe, Kolb, Hausdorf, & 
Haas, 1991; Walden, Altrup, Reith, & Speckmann, 1993; Grunze, Greene, Möller, Meyer, & 
Walden, 1998). It is, at this moment, purely speculative whether this action also contributes to 
mood stability. 
Effects of ACs on cellular resilience 
During the last decade, it has been demonstrated that not only lithium, but also VPA and, in 
part, CBZ regulate numerous factors enhancing cellular plasticity and resilience, including 
inositol biosynthesis (MIP synthase), cyclic adenine monophosphate (c-AMP) response 
element- binding protein, brain- derived neuotrophic factor (BDNF), the extracellular signal-
regulated kinase pathway, the arachidonic acid pathway, the cytoprotektive protein bcl-2 and 
mitogen-activated protein kinases (Chen & Manji, 2006; Bachmann et al., 2005; Chen, 
Huang, Zeng, & Manji, 2001; Williams, Cheng, Mudge, & Harwood, 2002; Chen et al., 2006; 
Shaltiel et al., 2004; Rao, Bazinet, Rapoport, & Lee, 2007b). 
The inositol phospholipid pathway might be more sensitive (and by this, vulnerable) in 
bipolar patients (Moscovich, Belmaker, Agam, & Livne, 1990). The impact of lithium on 
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cellular plasticity and resilience by targeting inositol monophosphatases (IMPases) and myo-
inositol uptake has been acknowledged for a while (Berridge & Irvine, 1989; van Calker & 
Belmaker, 2000); it is more recently that we became aware on the inhibitory effects of VPA 
and CBZ on inositol turnover (Lubrich & van Calker, 1999). VPA is also capable of inhibiting 
the synthesis of inositol monophosphate (Vaden, Ding, Peterson, & Greenberg, 2001). This 
also means a downstream reduction of the activation rate of Ca2+ calmodulin kinase II (CAM 
kinase II), an enzyme critically involved in long term synaptic changes (Lisman, 1994) and of 
myristoylated alanine- rich C kinase substrate (MARCKS) implicated in synaptic 
neurotransmission and cytoskeletal restructuring (Lenox & Watson, 1994). These effects may 
be important and inhibit structural changes of neurons seen in the course of the disease. 
However, other mechanisms may be at least of equal importance for the mood-stabilizing 
action of ACs. Glycogen synthase kinase -3 (GSK-3) is a serine/threonine kinase that appears 
to be a major regulator of apoptosis, neuronal resilience and circadian rythmicity. It is 
deactivated by numerous signalling pathways, including protein kinase A and C. VPA, and 
also some antidepressants, but not CBZ or LTG, inhibit GSK-3 (Chen, Huang, Jiang, & 
Manji, 1999; Zarate, Jr., Singh, & Manji, 2006), either directly or by interfering with one of 
the downstream mechanisms that normally would activate GSK-3. As GSK-3 may also play a 
crucial role in Alzheimer’s disease, the development of GSK-3 inhibitors is currently a major 
effort in pharmaceutical companies. 
Another more recently discovered effect of VPA is its action on the chaperones GRP 78, GRP 
94 and calreticulin. These endoplasmatic reticulum (ER) stress proteins bind calcium and are 
protective against cell death. Chronic treatment with VPA increases the synthesis of all three 
chaperones in rat C6 glioma cells, thus contributing to calcium homeostasis in the ER (Wang, 
Bown, Chen, & Young, 2001). 
A possible explanation for the delayed onset of action of several mood stabilizers (and 
antidepressants) is that they effect gene regulation in critical neuronal circuits. VPA might do 
so by acting as a histone deacetylase (HDAC) inhibitor (which may also account for its 
teratogenicity when taken during early pregnancy). This inhibition of HDAC has a multitude 
of downstream effects which, in summary, increase cellular plasticity and resilience ( for a 
detailed review, see (Zarate, Jr. et al., 2006) or (Bachmann et al., 2005)). 
Effects of ACs on HPA axis activity 
Dysregulation of the hypothalamic-pituitary-adrenocortical (HPA) axis has been 
demonstrated both in acutely ill and remitted bipolar patients (Watson, Gallagher, Ritchie, 
Ferrier, & Young, 2004). Little is known about direct effects of VPA and CBZ on HPA axis 
function. In the case of VPA, it may be rather unfavourable as Changes of HPA axis function 
has been implied in VPA induced polycystic ovary syndrome, although VPA may moderately 
decrease ACTH hypersecretion (Kasperlik-Zaluska, Zgliczynski, Jeske, & Zdunowski, 2005). 
Inhibitory effects of LTG on CRH release have been described in animals (Tringali, Aubry, 
Navarra, & Pozzoli, 2006) and it has been speculated that this, together with inhibition of 
ACTH (Jezova, 2005), may contribute to LTGs antidepressant and mood stabilising effects.  
Sensitization and kindling- behavioural models for the recurrent pattern of BD? 
 
Several aspects of depressive symptomatology can be modelled in  animal behaviour studies, 
i.e. learned helplessness paradigms or olfactory bulbectomized rats (Grunze, Schüle, Casey, & 
Baghai, 2008; Harkin, Kelly, & Leonard, 2006). Some animal models also resemble aspects 
of mania, e.g., administration of D-amphetamine. There is evidence that VPA prevents 
oxidative stress and DNA damage in this model (Andreazza et al., 2008). However, it is still  
difficult to explain specific characteristics of BD, such as opposing mood deflections and 
increasing vulnerability over the course of illness, in such models. Although still speculative 
in several aspects the sensitization and kindling model as described by Post and Weiss (Post 
& Weiss, 1996b) may be helpful in understanding BD, starting from a molecular level and 
evolving towards behavioural changes. 
Kraepelin (Kraepelin, 1921) noted that a marked psychosocial stressor is likely to precede the 
first affective episode, whereas subsequent episodes coincide only with minor or no notable 
life events. Over time, the frequency of episodes tends to increase, in some patients finally to 
autonomous rapid cycling, with decreasing efficacy of mood stabilizing drugs (Roy-Byrne, 
Post, Uhde, Porcu, & Davis, 1985). 
Post and co-workers (Post, Lockfeld, Squillace, & Contel, 1981) developed a model of 
cocaine- induced behavioural sensitisation (CIBS). Cocaine administration causes 
hyperlocomotion in rats and hypomanic-like symptoms in man. Repeated cocaine 
administration, however, may cause a shift of symptomatology toward signs of dysphoric 
mania (which has a high incidence in BD as shown by several studies (Goodwin & Jamison, 
2007)) or the development of paranoid symptoms. Animal lesion experiments in the amygdala 
show that CIBS involves different neuromodulatory changes depending on the duration and 
frequency of cocaine administration. Thus, not only does the symptomatology shift, but also 
the neuronal pathways involved, becoming independent from a direct action on the amygdala. 
Furthermore, cocaine is also capable to influence neuromodulators in a similar fashion as 
stress, i.e. an increase of CRF, ACTH, cortisol, cytokines, catecholamines and indoleamines. 
Relating these findings to intracellular, transcriptional processes, we note another important 
analogy to stress sensitization. Both conditions, CIBS and repeated stress, lead at the end of 
the intracellular signal transduction cascade  for the expression of immediate early genes (c-
fos and zif-268) in the amygdala and related limbic structures as well as late effector genes 
(LEG) (Smith, Makino, Kvetnansky, & Post, 1995). The composition of early genes and their 
occupation of the AP 1 receptor are partially specific for different stressors, e.g. 
electroconvulsive seizures or cocaine, as well as for mode of application, i.e. acute, repetitive 
or chronic. This may give a molecular background for speculations about how psychosocial 
stressors  cause symptoms of depression , whereas others, like acute pain, do not. Whereas 
early immediate gene activation primarily induces expression of genes such as for 
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neurotransmitter transporter, and presumably the acute symptomatology, induction of LEG’s 
as neurotropins and nerve growth factor (NGF) will modulate synaptic connectivity and nerve 
end sprouting and give rise to neuroanatomical  and long-term functional changes. 
Taken together, CIBS may be a useful model to study acute events and long term changes in 
symptomatology caused by episodes of affective disorders. However, to explain the aspect of 
sequential unfolding of episodes with increasing autonomy from the stressor, the amygdala 
kindled rat appears to be a suitable model. Kindling reflects a cumulative and progressive 
unfolding of physiological and behavioural changes in response to repeated stimulation over 
time which eventuates in seizures, first triggered and then occurring spontaneously. Although 
epileptic seizures may have some mechanisms in common with affective disorders (Gajwani 
et al., 2005), they are still two different conditions. But the rough anatomical substrate may be 
similar with the amygdaloid complex playing a key role in both disorders. Repeated electrical 
stimulation of the basolateral amygdala decreases the threshold for epileptic seizures often 
leading to spontaneous epileptic activity. The correlate of this at the synaptic level is an 
increase of both NMDA and non- NMDA receptor mediated glutamatergic transmission with 
a parallel decrease of inhibitory GABAergic transmission (Rainnie et al 1992). On the level of 
expression of early genes and neuropeptides, an increase of c-fos and TRH mRNA has been 
observed (Rosen, Cain, Weiss, & Post, 1992). With full manifestation of seizures, these 
changes on the synaptic level and substrate expression also involve the contralateral, non- 
stimulated amygdala complex. It is assumed that, similar to electrical kindling, recurrent 
affective episodes cause analogous long- term changes in neuronal networks, such as lowering 
the threshold for any consecutive episode. This hypothesis is backed up by a clinical study of 
Goldberg and Harrow (Goldberg & Harrow, 1994). Although having overall a comparable 
total number of previous episodes, patients who had a pattern of close periodicity of episodes 
in the past showed an increased relapse risk during follow up, interpreted as an indicator of a 
previous kindling process (Goldberg, Garno, & Harrow, 2005).  
A number of ACs (e.g., CBZ, VPA and LTG) efficacious in BD do exert antikindling 
properties. However, they all may develop contingent tolerance leading to insufficient 
suppression of seizures in the kindling model (Post et al., 1996b). On a clinical level, this may 
correspond to tolerance or drug resistance observed with long- term treatment and / or 
discontinuation of mood stabilizers as observed in some bipolar patients (Post & Weiss, 
2004).  
 
Clinical effectiveness of ACs in BD  
 
Several ACs have been tested in BD over the last decades. Currently licensed in this 
indication or at least used with good evidence are VPA, CBZ and LTG, but also phenytoin, 
oxcarbazepine, levetiracetam, topiramate, zonisamide and gabapentin may be beneficial in 
selected patients. 
Carbamazepine 
 
CBZ has traditionally been used in bipolar patients who were not sufficiently responding to 
lithium. It has proven antimanic efficacy (Owen, 2006) and few prophylactic benefits, 
although there is not very strong data to support this. (Smith, Cornelius, Warnock, Bell, & 
Young, 2007). Data on antidepressant efficacy of CBZ are much less robust and suggest, at its 
best, a mild to moderate effect (Post et al., 1996a). 
For mania, several comparator studies against lithium, VPA and first generation 
antipsychotics have been conducted. The impression of these studies was that CBZ was 
overall equally effective as comparators, with a probably slightly slower onset of response 
compared to neuroleptics (Brown, Silverstone, & Cookson, 1989) and VPA (Vasudev, 
Goswami, & Kohli, 2000), but slightly faster acting than lithium (Small, Klapper, Milstein, 
Marhenke, & Small, 1996).  
Comparing the prophylactic efficacy of CBZ against lithium, the two most recent studies 
suggest superiority of lithium treatment (Greil et al., 1997; Hartong, Moleman, Hoogduin, 
Broekman, & Nolen, 2003). However, CBZ appeared to be the better alternative for atypical 
manifestations of BD, such as a rapid cycling course, frequent recurrences of dysphoric or 
psychotic mania or other comorbid psychiatric or neurological conditions (Greil, Kleindienst, 
Erazo, & Müller-Oerlinghausen, 1998). A controlled study  (Denicoff et al., 1997), in rapid 
cycling patients  partially responsive to lithium, showed that the addition of CBZ  
significantly enhanced prophylactic efficacy . Another retrospective chart review by Baethge 
at al (Baethge et al., 2005) could also demonstrate additional efficacy from combination 
treatment with lithium and Carbamazepine compared to the respective monotherapies in 
Bipolar I patients. 
 
Valproate 
 
This article uses “valproate” (VPA) as the common generic name for the different 
preparations tested in BD, e.g., valproic acid, sodium valproate, divalproate, divalproex 
sodium, and valpromide. As far as pharmacokinetics and pharmacodynamics are concerned, 
only valproic acid finally reaches and penetrates the blood-brain barrier. Although tolerability 
is enhanced with extended release preparations these small differences do not justify grouping 
valproic acid derivatives as different medications. 
VPA is nowadays recommended as a first line treatment for acute mania (Grunze et al., 2009). 
The antimanic activity of VPA was first reported by Lambert (Lambert et al., 1966). 
Superiority against placebo has consequently been shown in several double-blind controlled 
monotherapy and add-on studies (Pope, McElroy, Keck, & Hudson, 1991; Bowden et al., 
1994; Müller-Oerlinghausen, Retzow, Henn, Giedke, & Walden, 2000; Bowden et al., 2006); 
however, it failed to separate from placebo in only mild to moderate mania (Tohen et al., 
2008). In comparator trials, VPA showed equal efficacy as lithium (Freeman, Clothier, 
Pazzaglia, Lesem, & Swann, 1992; Bowden et al., 1994; Bowden et al., 2008), haloperidol 
(McElroy et al., 1996) and in one study against olanzapine (Zajecka et al., 2002), but not in 
two others (Zajecka et al., 2002; Tohen et al., 2008). Compared to lithium, VPA appears 
especially effective in conditions less responsive to lithium such as mixed states (Swann et al., 
1997). In comparison to CBZ, VPA appeared overall to be more efficacious in mania 
(Vasudev et al., 2000). For bipolar depression, two small placebo controlled studies have been 
published showing significant effects (Davis, Bartolucci, & Petty, 2005; Ghaemi et al., 2007), 
but confirmative studies are still awaited. 
The only large scale randomised maintenance study comparing VPA against placebo and 
lithium could not prove efficacy either for VPA or lithium for the primary outcome criterion 
(time to any mood episode). Looking at secondary outcome parameters show some potentially 
clinically useful information was detected, e.g., VPA was significantly better than placebo in 
preventing new depressive episodes. In addition, patients who were previously responsive to 
VPA when treated for an acute episode also performed better when randomised on VPA 
maintenance treatment compared when randomised on lithium or placebo. When reanalysing 
this study together with other, smaller studies a meta-analysis was able to support 
prophylactic efficacy of VPA at least for depressive relapses (Smith et al., 2007). 
Lamotrigine  
 
In contrast to CBZ and VPA, LTG seems to exert its main efficacy in the prophylaxis of 
bipolar depression. Two controlled acute mania studies with LTG were both negative. Of the 
sponsored Phase III studies in acute bipolar depression, only one study showed a positive 
result in a secondary outcome parameter (Calabrese et al., 1999), whereas four further studies 
failed to separate from placebo. However, a recent add- on study showed antidepressant 
efficacy of LTG in combination with lithium (van der Loos et al., 2009). In direct (but 
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underpowered) comparison to other treatment modalities of acute bipolar depression, LTG 
was equally effective as citalopram (Schaffer, Zuker, & Levitt, 2006), but less effective than 
tranylcypromine (Nolen et al., 2007). LTG was also less effective than the olanzapine/ 
fluoxetine combination in a comparator trial, but appeared better tolerated and safer as far as 
the metabolic profile was concerned (Brown et al., 2006). 
The main area of application of LTG in BD is maintenance treatment. Two double-blind, 
randomized maintenance trials over 18 months proved efficacy of LTG when compared to 
placebo and lithium. Both LTG and lithium were superior to placebo. Looking for differential 
rates of relapse, LTG was more effective in preventing new depressive episodes, whereas 
lithium was better in preventing manic episodes (Goodwin et al., 2004).  
Other ACs 
 
Several other ACs have been proposed as having efficacy in BD, but none of them have been 
studied enough to allow the conclusion that efficacy and tolerability were within the same 
range as the drugs previously reviewed more in detail. Additionally, substantial evidence of 
marginal or unsatisfactory tolerability exists, and/or evidence of lack of difference from 
placebo in mania trials is conclusive.  
Phenytoin has demonstrated antimanic and prophylactic properties, but no antidepressant 
action in randomized, placebo controlled studies (Mishory, Yaroslavsky, Bersudsky, & 
Belmaker, 2000; Mishory, Winokur, & Bersudsky, 2003; Bersudsky, 2006) This has been 
interpreted as potential proof of the involvement of sodium channel dysregulation in manic 
states. However, other mechanisms such as anti-glucocorticoid mechanism also appear 
possible (Gallagher, Reid, & Watson, 2006). The side effect profile of phenytoin, especially 
cognitive side effects and cerebellar atrophy (De Marcos, Ghizoni, Kobayashi, Li, & Cendes, 
2003), however, makes it a medication of subordinate choice in BD. 
Evidence for the efficacy of oxcarbazepine in BD is not convincing; a recent review of 
several small, underpowered or placebo-uncontrolled studies came to the conclusion that it 
may be useful in treating manic symptoms (Popova, Leighton, Bernabarre, Bernardo, & Vieta, 
2007), but conclusive evidence is lacking. In addition, a randomized, controlled study in 
adolescent mania failed to separate oxcarbazepine from placebo (Wagner et al., 2006)  Thus, 
the case for oxcarbazepine in acute mania is rather weak. As far as bipolar depression and 
prophylactic treatment are concerned, no evidence from methodologically rigorous trials is 
available. 
Due to the chemical resemblance with CBZ it is often assumed that oxcarbazepine may be 
beneficial in patients who previously responded well to CBZ but had to discontinue it for 
reasons of tolerability or interaction with other medication. Oxcarbazepine may also exhibit 
interactions with other medications and tolerability issues, but to a lesser degree than CBZ 
(Andreasen, Brosen, & Damkier, 2007). However, the risk of hyponatremia appears to be 
greater with oxcarbazepine. 
Based on the GABA hypothesis of BD, expectations were high when gabapentin was 
introduced. However, two add-on studies in acute mania could not prove efficacy (Pande, 
Crockatt, Janney, Werth, & Tsaroucha, 2000; Frye et al., 2000); in fact, gabapentin performed 
even worse than placebo in one of them (Pande et al., 2000). For bipolar depression, open 
augmentation studies suggest some efficacy in the absence of controlled data (Wang et al., 
2002; Altshuler et al., 1999). As far as long term treatment is concerned, a recent controlled 
maintenance study suggests that maintenance treatment with gabapentin can be beneficial in 
some patients (Vieta et al., 2006), but larger replication studies are needed. 
 For levetiracetam, positive open studies in acute mania (Goldberg & Burdick, 2002; Grunze, 
Langosch, Born, Schaub, & Walden, 2003; Kyomen, 2006; Kruger, Sarkar, Pietsch, 
Hasenclever, & Braunig, 2008) have been reported, but controlled evidence is again missing. 
More recently, a 31% remission rate was reported in patients with BD who were in the 
Deleted: as a matter of
depressed phase at baseline and who received levetiracetam as add-on therapy for 8 weeks in 
an open-label trial (Muralidharan & Bhagwagar, 2006). 
Other modern antiepileptic drugs, such as tiagabine, retigabine and pregabalin, appear not 
to be promising in BD (Suppes et al., 2002; Grunze et al., 1999; Amann et al., 2006; Carta, 
Hardoy, Grunze, & Carpiniello, 2002; Young, Geddes, Macritchie, Rao, & Vasudev, 2006; 
Young et al., 2006). Topiramate first appeared to be a promising candidate in pilot studies, 
however, five double-blind, randomised studies could not prove efficacy in acute mania 
(Kushner, Khan, Lane, & Olson, 2006; Roy Chengappa, Schwarzman, Hulihan, Xiang, & 
Rosenthal, 2006). A single-blind comparator study against bupropion suggests some efficacy 
of topiramate in bipolar depression (McIntyre et al., 2002). Nevertheless, due to their weight 
reducing effect topiramate as well as zonisamide, which showed distinct antimanic and 
antidepressant properties in open trials (Anand et al., 2005; Ghaemi et al., 2006; Kanba et al., 
1994; McElroy et al., 2005; Wilson & Findling, 2007) may still be options as an add-on 
treatment in patients who massively gain weight with established mood stabilisers.  
 
 
Conclusions 
 
CBZ, VPA and LTG are nowadays established treatment options in BD. They greatly enrich 
our treatment portfolio, especially in mania and maintenance treatment. CBZ, VPA and LTG 
share some mechanisms of action with each other, but also with lithium. However, it remains 
unclear which of their multiple site actions are more and which less decisive for efficacy in 
BD. It appears likely that these ACs will not be the last that will enter the field of BD. There 
is a multitude of new ACs currently in the pipeline, although at the moment it is unclear 
which of these will be tested in BD. Seletracetam which inhibits intracellular calcium release, 
losigamone with activity on GABA-A receptor linked chloride channels, ganaxolone as 
agonist at GABA-A receptor sites, or lacosamide, being both a sodium channel blocker and 
binding intracellularly to collapsin response mediator protein-2 (CRMP-2) all might develop 
as further substances with potential value in the treatment of BD. 
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